News + Filings Holdings
All
13F
13D/G
Other
|
|
TCG Crossover Management, LLC
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/15/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/19/2022 |
SC 13G
| TCG Crossover Management, LLC reports a 5.9% stake in Silence Therapeutics plc |
| 08/15/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/16/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/17/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/29/2021 |
SC 13G
| TCG Crossover Management, LLC reports a 7% stake in CymaBay Therapeutics, Inc. |
| 11/17/2021 |
SC 13G/A
| TCG Crossover Management, LLC reports a 6.8% stake in Cogent Biosciences, Inc. |
| 09/29/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 09/29/2021 |
SC 13G/A
| TCG Crossover Management, LLC reports a 2.2% stake in Tyra Biosciences, Inc. |
| 09/24/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 09/21/2021 |
SC 13G
| TCG Crossover Management, LLC reports a 8.7% stake in Tyra Biosciences, Inc. |
| 09/10/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/08/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
|
|